<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 7:Effect of Other Drugs on Voriconazole Pharmacokinetics [ see Clinical Pharmacology (<linkhtml href="#Lf470d655-ab23-4c18-b63c-ca1e60b32500">12.3</linkhtml>)]</caption>
<colgroup>
<col width="34%"></col>
<col width="33%"></col>
<col width="33%"></col>
</colgroup>
<thead>
<tr stylecode="First Last">
<td align="center" stylecode="Botrule Lrule Rrule Toprule">
<content stylecode="bold"> Drug/Drug Class</content>
<br/>
<content stylecode="bold">(Mechanism of Interaction by the Drug)</content>
</td>
<td align="center" stylecode="Botrule Rrule Toprule">
<content stylecode="bold"> Voriconazole Plasma Exposure</content>
<br/>
<content stylecode="bold">(Cmax and AUC after 200 mg q12h)</content>
</td>
<td align="center" stylecode="Botrule Rrule Toprule">
<content stylecode="bold">Recommendations for Voriconazole Dosage Adjustment/Comments</content>
</td>
</tr>
</thead>
<tfoot>
<tr stylecode="First Last">
<td colspan="3">* Results based on in vivo clinical studies generally following repeat oral dosing with 200 mg q12h voriconazole to healthy subjects<br/>** Results based on in vivo clinical study following repeat oral dosing with 400 mg q12h for 1 day, then 200 mg q12h for at least 2 days voriconazole to healthy subjects<br/>*** Non-Nucleoside Reverse Transcriptase Inhibitors</td>
</tr>
</tfoot>
<tbody>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">Rifampin* and Rifabutin*<br/>(CYP450 Induction)</td>
<td align="center" stylecode="Botrule Rrule">Significantly Reduced</td>
<td align="center" stylecode="Botrule Rrule">
<content stylecode="bold">Contraindicated</content>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule Rrule">
<paragraph>Efavirenz (400 mg q24h)**<br/>(CYP450 Induction)</paragraph>
<paragraph></paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>Significantly Reduced</paragraph>
<paragraph></paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule"></td>
<td></td>
<td stylecode="Rrule"></td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">
<paragraph>Efavirenz (300 mg q24h)**<br/>(CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Slight Decrease in AUCτ</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>When voriconazole is coadministered with efavirenz, voriconazole oral maintenance dose should be increased to 400 mg q12h and efavirenz should be decreased to 300 mg q24h</paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule Rrule">
<paragraph>High-dose Ritonavir (400 mg q12h)**<br/>(CYP450 Induction)</paragraph>
<paragraph></paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>Significantly Reduced</paragraph>
<paragraph></paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
<paragraph></paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule"></td>
<td></td>
<td stylecode="Rrule"></td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule"> Low-dose Ritonavir (100 mg q12h)**<br/>(CYP450 Induction)</td>
<td align="center" stylecode="Botrule Rrule">Reduced </td>
<td align="center" stylecode="Botrule Rrule">Coadministration of voriconazole and low-dose ritonavir (100 mg q12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">Carbamazepine<br/>(CYP450 Induction)</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
<paragraph></paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">Long Acting Barbiturates<br/>(CYP450 Induction)</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Not Studied <content stylecode="italics">In Vivo</content> or <content stylecode="italics">In Vitro</content>, but Likely to Result in Significant Reduction</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
<paragraph></paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">Phenytoin*<br/>(CYP450 Induction)</td>
<td align="center" stylecode="Botrule Rrule">Significantly Reduced</td>
<td align="center" stylecode="Botrule Rrule">Increase voriconazole maintenance dose from 4 mg/kg to 5 mg/kg IV q12h or from 200 mg to 400 mg orally q12h (100 mg to 200 mg orally q12h in patients weighing less than 40 kg)</td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">St. Johns Wort<br/>(CYP450 inducer; P-gp inducer)</td>
<td align="center" stylecode="Botrule Rrule">Significantly Reduced</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>
<content stylecode="bold">Contraindicated</content>
</paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">
<paragraph>Oral Contraceptives**</paragraph>
<paragraph>containing ethinyl estradiol and norethindrone (CYP2C19 Inhibition)</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Increased</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Monitoring for adverse events and toxicity related to voriconazole is recommended when coadministered with oral contraceptives</paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule">
<paragraph>Fluconazole** (CYP2C9, CYP2C19 and CYP3A4 Inhibition)</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Significantly Increased</paragraph>
</td>
<td align="center" stylecode="Botrule Rrule">
<paragraph>Avoid concomitant administration of voriconazole and fluconazole. Monitoring for adverse events and toxicity related to voriconazole is started within 24 h after the last dose of fluconazole.</paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule Rrule">
<paragraph>Other HIV Protease Inhibitors<br/>(CYP3A4 Inhibition)</paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>
<content stylecode="italics">In Vivo</content> Studies Showed No Significant Effects of Indinavir on Voriconazole Exposure</paragraph>
<paragraph></paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>No dosage adjustment in the voriconazole dosage needed when coadministered with indinavir</paragraph>
<paragraph></paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule Rrule"></td>
<td align="center" stylecode="Rrule"></td>
<td align="center" stylecode="Rrule"></td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule"></td>
<td align="center" stylecode="Botrule Rrule">In Vitro Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism (Increased Plasma Exposure)</td>
<td align="center" stylecode="Botrule Rrule">Frequent monitoring for adverse events and toxicity related to voriconazole when coadministered with other HIV<br/>protease inhibitors</td>
</tr>
<tr valign="top">
<td stylecode="Lrule Rrule">
<paragraph>Other NNRTIs***<br/>(CYP3A4 Inhibition or CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>
<content stylecode="italics">In Vitro</content> Studies Demonstrated Potential for Inhibition of Voriconazole Metabolism by Delavirdine and Other NNRTIs (Increased Plasma Exposure)</paragraph>
<paragraph></paragraph>
</td>
<td align="center" stylecode="Rrule">
<paragraph>Frequent monitoring for adverse events and toxicity related to voriconazole</paragraph>
<paragraph></paragraph>
</td>
</tr>
<tr valign="top">
<td stylecode="Lrule Rrule"></td>
<td align="center" stylecode="Rrule"></td>
<td align="center" stylecode="Rrule"></td>
</tr>
<tr valign="top">
<td stylecode="Botrule Lrule Rrule"></td>
<td align="center" stylecode="Botrule Rrule">A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure)</td>
<td align="center" stylecode="Botrule Rrule">Careful assessment of voriconazole effectiveness</td>
</tr>
</tbody>
</table>